I-MAB (IMAB) Other Current Payables : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is I-MAB Other Current Payables?

I-MAB's Other Current Payables for the quarter that ended in Sep. 2024 was $0.00 Mil.

I-MAB's quarterly Other Current Payables declined from Dec. 2023 ($11.98 Mil) to Jun. 2024 ($0.00 Mil) but then stayed the same from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil).

I-MAB's annual Other Current Payables increased from Dec. 2021 ($8.24 Mil) to Dec. 2022 ($16.73 Mil) but then declined from Dec. 2022 ($16.73 Mil) to Dec. 2023 ($11.98 Mil).

I-MAB Other Current Payables Historical Data

The historical data trend for I-MAB's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Other Current Payables Chart

I-MAB Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Payables

Get a 7-Day Free Trial

6.63

34.12

8.24

16.73

11.98

I-MAB Quarterly Data
	Dec17	Jun18	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24
Other Current Payables	Get a 7-Day Free Trial														-	-	11.98	-	-

I-MAB Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

I-MAB Other Current Payables Related Terms

Thank you for viewing the detailed overview of I-MAB's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Other Current Payables

Comparable Companies

Traded in Other Exchanges

0VY:Germany

Address

2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850

Website

https://www.i-mabbiopharma.com

I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).